Vaccine maker Novavax (NASDAQ:NVAX) saw its shares jump 18% on June 5 and another 20% in pre-market trade this morning. NVAX stock is up over 300% year-to-date. NVAX stock is due to open today at $24.10 per share, a market capitalization of about $3.6 billion on 2023 revenue of $656 million. But Novavax lost the race to deliver its vaccines to Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). Shares fell to below $10 in 2023. Talk show host Peter Sagal recently missed a show because of Covid. Singer Linda Ronsta ...

Novavax (NASDAQ:NVAX) is on a recovery trek after collapsing in late 2021. Recently, management said that its latest vaccine version addressing newer Covid-19 subvariants is more effective than older injections. According to a Reuters report, vaccine makers presented animal study data which "showed their 2024-25 shots targeting the JN.1 variant that was dominant earlier this year could neutralize newer subvariants such as KP.2 much better than the older shots." Novavax and other vaccine developers, includin ...

In this meeting, members of the VRBPAC will discuss whether to update the currently authorized COVID-19 vaccines to target the JN.1 variant. This was also recommended by a World Health Organization (WHO) advisory committee on Apr 26. Shares of COVID-19 vaccine developers rose on Monday after the FDA issued briefing documents for its Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Jun 5 to consider the selection of the 2024-2025 formula for COVID-19 vaccines. The FDA pointed o ...

GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Contacts: Investors Erika Schultz 240-268-2022 [email protected] Media Giovanna Chandler 240-720-7804 [email protected] About Novavax | Fireside Chat | | | --- | --- | | Date: | Thursday, June 6, 2024 | | Time: | 12:30 – 12:55 p.m. Eastern Time (E ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this vaccine maker have returned +261.3% over the past month versus the Zacks S&P 500 composite's +4.2% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has gained 6.2% over this period. Now the key question is: Where could the stock be headed in the near term? Although medi ...

Novavax (NASDAQ:NVAX) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5. However, with the company announcing a deal with Sanofi (NASDAQ:SNY), the stock skyrocketed by 280% last month. With the likelihood of the return of the meme stock frenzy, it's a good time to look at biotech stocks to buy for returns that can replicate the performance of NVAX stock. Therefore, I am looking at speculative ideas ...

Both biotechs have been struggling for a while, but there might be some hope for them. The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful. That group includes Novavax (NVAX 6.71%) and Inovio Pharmaceuticals (INO 0.94%). The former did launch a coronavirus vaccine in the U.S., but the latter never got that far. Finally, Novavax has implemented a more disciplined app ...

The vaccine maker's recovery story is looking brighter. Novavax (NVAX 0.81%) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock to a 2,700% gain back in 2020. But when Novavax fell behind on the road to commercialization, the shares declined -- and even the eventual regulatory approval and market entry of that vaccine didn't much help. In recent times, though, Novavax has taken steps t ...

In addition to the above deal, Sanofi also agreed to make an equity investment of nearly $70 million in Novavax in exchange for a 4.9% stake. Shah Capital launched its proxy fight days before the deal with Sanofi was announced, urging investors to vote against three incumbent directors and opposed proposals related to executive compensation at the company's annual meeting on Jun 13. Despite the campaign withdrawal, Shah will continue to monitor the company as it believes that 'significant additional value r ...

The price-action in some speculative stocks in the recent past is signaling the possible return of the meme stock euphoria. Stocks like Novavax (NASDAQ:NVAX) doubled overnight, and the rally has even increased. It's, therefore, a good time to make quick money by holding positions in some cheap speculative stocks. Regarding the fundamentals, Riot has a cash buffer of $1.3 billion (including the value of Bitcoin holdings). Further, the company has a zero-debt balance sheet. This positions Riot to pursue aggre ...